Global Pneumococcal Vaccine Market accounted for US$ US$8.1 billion in 2020 and is estimated to be US$ 13.5 billion by 2030 and is anticipated to register a CAGR of 5.3%. Serious and potentially fatal pneumococcal infections is protected by the pneumococcal vaccine. It's also known as the pneumonia vaccine. Pneumococcal infections caused by the bacterium Streptococcus pneumonia which lead to pneumonia, septicemia (a kind of blood poisoning) and meningitis. All adults (65 years or older) should receive dose of pneumococcal polysaccharide vaccine (PPSV23). In addition, CDC recommends PCV13 based on shared clinical decision-making for adults 65 years or older who do not have an immune compromising condition, cerebrospinal fluid leak, or cochlear implant.

The report "**Global Pneumococcal Vaccine Market, By Vaccine type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), By Product Type (Prevnar 13, Synflorix, Pneumovax 23), By Sector (Public and Private), By Distribution Channel (Distribution Partner Companies, Non-Governmental Organization, Government Authorities) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”**

**Key Highlights:**

* World Health Organization (WHO) estimated that 1.6 million people die of pneumococcal disease every year; this estimate includes the deaths of 0.7-1 million children aged less than 5 years, most of whom live in developing countries.
* Pfizer’s Prevnar 13 follow-up, a 20-strain pneumococcal shot has been set for an FDA filing later this year, with a possible approval in the middle of 2021.

**Analyst View:**

Adoption of pneumococcal vaccines has shown significant growth due to focus of governmental and non- governmental bodies. Moreover, rise in prevalence of pneumonia within the developing countries further boost the market. Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) and Gates Foundation are the non-governmental organizations which encourages the manufacturers to develop novel vaccines to cater large population.

*Browse 60 market data tables\* and 35 figures\* through 140 slides and in-depth TOC on “Global Pneumococcal Vaccine Market, By Vaccine type (Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine), By Product Type (Prevnar 13, Synflorix, Pneumovax 23), By Sector(Public and Private), By Distribution Channel (Distribution partner companies, Non-governmental organization, Government Authorities) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”*

*To know the upcoming trends and insights prevalent in this market, click the link below****:***

[*https://www.prophecymarketinsights.com/market\_insight/global-pneumococcal-vaccine-market-4632*](https://www.prophecymarketinsights.com/market_insight/global-pneumococcal-vaccine-market-4632)

**Key Market Insights from the report:**

The global pneumococcal vaccine market accounted for US$ 8.1 billion in 2020 and is estimated to be US$ 13.5 billion by 2030 and is anticipated to register a CAGR of 5.3%. The global pneumococcal vaccine market is segmented based on the vaccine type, product type, sector, distribution channel and region.

* By vaccine type, the global pneumococcal vaccine market is segmented into Pneumococcal conjugate vaccine and Pneumococcal polysaccharide vaccine.
* By product type, the market is segmented in Prevnar 13, Synflorix and Pneumovax 23.
* By sector, the global pneumococcal vaccine market is segmented into Public and Private.
* By distribution channel, the Global Pneumococcal Vaccine Market is segmented into Distribution partner companies, Non-governmental organizations and Government authorities.
* By region, the global pneumococcal vaccine market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the worldwide leader in the pneumococcal vaccine market in terms of revenue, due to the developed healthcare system and health awareness among people.

**Competitive Landscape:**

The key players operating in the global pneumococcal vaccine market include Pfizer, Merck, Glaxosmith Kline plc, Astra Zeneca, Baxter International, Sanofi Pasteur MSD, CSL Ltd, Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited), SK Bioscience and Walvax Biotechnology Co., Ltd.

Other Related Topics:

<https://www.digitaljournal.com/pr/waste-or-garbage-collection-vehicle-market-size-shares-and-analysis-trends-with-top-most-key-players-mack-autocar-trucks-environmental-solutions-group>

<https://www.digitaljournal.com/pr/first-and-last-mile-delivery-market-size-shares-and-analysis-trends-with-top-most-key-players-cargo-carriers-limited-fedex-corporation-united-parcel-service-inc>